The largest database of trusted experimental protocols

Rhepo

Manufactured by Roche
Sourced in Germany, Switzerland, United Kingdom

RhEpo is a laboratory equipment product manufactured by Roche. It is used to measure the levels of erythropoietin (EPO), a hormone that regulates red blood cell production, in biological samples. The core function of RhEpo is to provide accurate and reliable EPO quantification for research and clinical applications.

Automatically generated - may contain errors

5 protocols using rhepo

1

Neural Stem Cell Migration Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Neurospheres in the range of 100–200 μm were seeded on coverslips coated with as before to evaluate the influence of coating concentration on expansion of the neurosphere as a measurement of migration. Alternatively, fixed concentrations of 50 μg/ml of either PDL or PornT was used to evaluate the response of the spheres to proteins known to influence the migration and differentiation of NPCs depending on the coating of choice. In the latter case neurospheres were stimulated with 500 ng/μl of stromal-cell derived factor-1alpha (SDF-1a, R&D systems, Germany) or 50 IU/ml of rhEpo (NeoRecormon, Roche, Switzerland). Expansion was tracked for 8 h on a Zeiss inverted microscope equipped with a cell culture chamber. Images were taken every 10 min with a 10x phase contrast objective. Expansion of the spheres was analyzed using custom designed macros on ImageJ. The increase in area occupied by the neurosphere was calculated as rA=fAiA , where, rA is the ratio of the sphere area, fA is the area at the end of the recording, and iA is the area at the beginning of the recording. Data is represented as ratio of the respective control (Figures 7 and 8) or as rA (Supplementary Figure S1). At least 10 neurospheres were tracked in a total of 3–4 experiments per evaluated condition.
+ Open protocol
+ Expand
2

Single Cell Culture and Expansion

Check if the same lab product or an alternative is used in the 5 most similar protocols
Single cells were sorted and cultured in 96-well plates in StemSpan SFEM medium (STEMCELL Technologies, Cat. 09600) supplemented with 20 ng/ml rmSCF (Peprotech, 250-03), 20 ng/ml rmTPO (eBioscience, 34-8686-63), 20 ng/ml rmIl3 (Peprotech, 213-13), and 5 U/ml rhEpo (Roche) and cultivated for 12 days at 37 °C with 5% CO2.
+ Open protocol
+ Expand
3

EPO Therapy for Post-HI Injury

Check if the same lab product or an alternative is used in the 5 most similar protocols
Animals showing injury on initial MRI were selected and randomized to NaCl group, injected intraperitoneally with NaCl 0.9% or to EPO group, injected intraperitoneally with recombinant human EPO (rhEPO, Roche, Basel, Switzerland) 10 U/g body weight/day during the first week after HI (P3 to P10) and then 5 U/g body weight 3×/week until P25. A Control group, which was not subjected to surgery and injection, was also studied.
+ Open protocol
+ Expand
4

Recombinant Human Erythropoietin for Preterm Infants

Check if the same lab product or an alternative is used in the 5 most similar protocols
The RHEpo intervention was r3 single doses of 3000 IU RHEpo (Roche) per kg body weight dissolved in 1 mL distilled water; the placebo control was an equivalent volume of sodium chloride 0.9% (placebo). Doses were administered intravenously within 3 hours, at 12 to 18 hours after birth, and at 36 to 42 hours after birth. The maximal dose was 1.5 mL (4500 IU; 37.5 μg) RHEpo for infants weighing 1.5 kg or more. The vials of the study medication were prepared in 1 study center (Zurich) according to a randomization list stratified per center then labeled, shipped, and stored in conformity with the Swiss Therapeutic Products Act. The study medication was randomly assigned to the patient number using a computer-based random-number generator. Multiples were randomized to the same treatment group. Parents, health care practitioners, and investigators were blinded to the treatment allocation.
+ Open protocol
+ Expand
5

Epo and Splice Variant Effects on Cultured Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Four-day-old primary cultures were maintained in L-15 medium supplemented with 0.5% gentamicin. Particular cultures were incubated with different concentrations (0.32 ng/ml, 0.8 ng/ml, 3.2 ng/ml, 8 ng/ml, 32 ng/ml) of recombinant human Epo (rhEpo, NeoRecormon, Roche, Welwyn Garden City, UK) or (0.42 ng/ml, 0.84 ng/ml) of the human non-erythropoietic Epo splice variant EV-3 (IBA GmbH, Göttingen, Germany) for another 3 days. Cell cultures were fixed in paraformaldehyde (4%, 30 min), labeled with DAPI (Sigma-Aldrich, Munich, Germany; 1:1000) and mounted with DABCO (Roth, Karlsruhe, Germany) on microscopic slides to quantify cellular survival (see below).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!